• Estelle® oral contraceptive now available in the United States

    Monday June 21st 2021

  • Mithra completes recruitment of Covid-19 Phase II Study

    Thursday June 17th 2021

  • Biotalys’ ongoing trial program demonstrates strong potential of its new generation protein-based biocontrols

    Thursday June 17th 2021

  • argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology

    Thursday June 17th 2021

  • Biocair moves into new Frankfurt office, continuing global expansion

    Thursday June 17th 2021

  • Commercial Agency Agreement between Ardena and South Korean company Keyfronbio Co., Ltd.

    Wednesday June 16th 2021

  • Biotalys announces intention to launch an Initial Public Offering on Euronext Brussels

    Tuesday June 15th 2021

  • Vacature: Manager Studiedienst (m/v/x) bij flanders.bio

    Monday June 14th 2021

  • Your news here?

  • Montis Biosciences awarded VLAIO grant to expand its pipeline of novel immune-oncology therapeutics

    Monday June 14th 2021

  • Precigen ActoBio announces positive topline results from Phase 1b/2a Study of AG019 ActoBiotics™

    Monday June 14th 2021

  • OXURION confirms Institutional Review Board approval and submission of the Investigational New Drug Application to the FDA to start Phase 2 Study evaluating THR-687 for Diabetic Macular Edema (DME)

    Thursday June 10th 2021

Strategic Partners